Transgenic plants as protein factories

Area of Science:

• Biotechnology
• Molecular Biology
• Plant Science

Background:

• Transgenic plants are emerging as a viable platform for cost-effective protein production.
• Several protein products derived from transgenic plants are already commercially available.
• Advancements in understanding protein targeting and accumulation are key to optimizing this technology.

Purpose of the Study:

• To highlight the economic potential of transgenic plants for protein manufacturing.
• To discuss the clinical progress and safety profile of plant-produced pharmaceuticals.
• To emphasize the role of improved protein targeting in enhancing the utility of transgenic plant technology.

Main Methods:

• Review of current literature on transgenic plant protein production.
• Analysis of clinical trial data for plant-derived pharmaceuticals.
• Examination of research on protein targeting and accumulation mechanisms in plants.

Main Results:

• Transgenic plants demonstrate significant economic viability for protein production, with marketed products.
• Clinical trials indicate encouraging safety and efficacy of pharmaceuticals produced in transgenic plants.
• Plant glycans exhibit low immunogenicity, a favorable characteristic for therapeutic proteins.

Conclusions:

• Transgenic plant technology holds substantial promise for the economical and safe production of therapeutic proteins.
• The favorable immunogenicity of plant glycans supports their use in pharmaceutical development.
• Continued research into protein targeting and accumulation will further unlock the potential of this biotechnological approach.